FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
AFT Leaves X Over AI-Generated Images of Minors 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
CAMBRIDGE, Mass., March 29, 2017 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a company overview at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 9:20 a.m. ET in New York City.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.
About Genocea Biosciences Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLASTM, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea’s pipeline includes GEN-003, a novel T cell-enabled immunotherapy for genital herpes currently in Phase 2 clinical development, and earlier-stage investments in immuno-oncology. For more information, please visit the company's website at www.genocea.com.
For media: Jennifer LaVin O: 617-715-6687 [email protected] For investors: Jonathan Poole O: 617-876-8191 [email protected]
